A Phase 1 interventional study of Taladegib in Advanced Cancer, sponsored by Eli Lilly and Company. Completed at 12 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-13.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to find a recommended dose level and schedule of dosing LY2940680 that can safely be taken by participants with advanced cancer. The study will also explore the changes in a cancer marker level in skin, hair follicles, buccal cells, and tumor cells. Finally, the study will help document any antitumor activity this drug may have.
Participants may include those who have previously received treatment with another hedgehog smoothened (Hh/Smo) inhibitor (excluding LY2940680).
10,826 studies on the registry are indexed under Neoplasms; 2,325 are open to participants now.
This study's enrollment of 84 is above the median of 60 across 7,706 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Have adequate organ function, including:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Part A Cohort 1: 50 milligram (mg) taladegib administered orally QD on a 28-day cycle. Part A Cohort 2: 100 mg taladegib administered orally QD on a 28-day cycle. Part A Cohort 3: 200 mg taladegib administered orally QD on a 28-day cycle. Part A Cohort 4: 400 mg taladegib administered orally QD on a 28-day cycle. Part A Cohort 5: 600 mg taladegib administered orally QD on a 28-day cycle. Part C: 400 mg taladegib administered orally QD. Participants with advanced solid tumors. Part D: 400 mg taladegib administered orally QD. Participants with advanced basal cell carcinoma (BCC).
Drug: Taladegib
Administered IV
Also known as: LY2940680
Recommended Phase 2 Dose: Maximum Tolerated Dose
Recommended Phase 2 dose was determined by maximum tolerated dose (MTD), which was determined by Dose-limiting toxicity (DLT). For the purpose of this study, the MTD was defined as the highest tested dose that had \<33% probability of causing a DLT in Cycle 1 of Part A.
Time frame: Time to First Dose to the End of Cycle 1 of Part A (Up To 28 Days)
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞])
Pharmacokinetics (PK): 1.Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC\[0-∞\])
Time frame: Cycle 1, Day 1: Predose, 0.5, 1, 2, 4, 6, 8, 10,11, 12 hour(h), Day 15: Predose, 0.5, 1, 2, 4, 6, 8, 10,11, 12 h
PK: Maximum Observed Drug Concentration (Cmax)
PK: Maximum Observed Drug Concentration (Cmax)
Time frame: Cycle 1, Day 1: Predose, 0.5, 1, 2, 4, 6, 8, 10,11, 12 hour(h), Day 15: Predose, 0.5, 1, 2, 4, 6, 8, 10,11, 12 h
PK: Time of Maximal Concentration (Tmax)
PK: Time of Maximal Concentration (Tmax)
Time frame: Cycle 1, Day 1: Predose, 0.5, 1, 2, 4, 6, 8, 10,11, 12 hour(h), Day 15: Predose, 0.5, 1, 2, 4, 6, 8, 10,11, 12 h
PK: Area Under the Plasma Concentration-time Curve From Time Zero to 24 Hours (AUC[0-24]) of LSN3185556
PK: Area Under the Plasma Concentration-time Curve from time Zero to 24 Hours (AUC\[0-24\]) of LSN3185556
Time frame: Cycle 1, Day 1: Predose, 0.5, 1, 2, 4, 6, 8, 10,11, 12 hour(h), Day 15: Predose, 0.5, 1, 2, 4, 6, 8, 10,11, 12 h
PK: Maximum Observed Drug Concentration (Cmax) of LSN3185556
PK: Maximum Observed Drug Concentration (Cmax) of LSN3185556
Time frame: Cycle 1, Day 1: Predose, 0.5, 1, 2, 4, 6, 8, 10,11, 12 hour(h), Day 15: Predose, 0.5, 1, 2, 4, 6, 8, 10,11, 12 h
PK: Time of Maximal Concentration (Tmax) of LSN3185556
PK: Time of Maximal Concentration (Tmax)
Time frame: Cycle 1, Day 1: Predose, 0.5, 1, 2, 4, 6, 8, 10,11, 12 hour(h), Day 15: Predose, 0.5, 1, 2, 4, 6, 8, 10,11, 12 h
Number of Participants With Clinical Benefit Rate (Stable Disease [SD] + Partial Response [PR] + Complete Response [CR])
Clinical Benefit Rate is complete response (CR) + partial response (PR) + stable disease (SD) as classified by the investigator according to the Response Evaluation Criteria In Solid Tumors (RECIST version 1.1) guidelines. CR is disappearance of all target and non-target lesions; PR is ≥30% decrease in sum of longest diameter of target lesions. SD is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD). PD is a ≥20% increase in the sum of diameter of the target lesions taking as reference the smallest sum on study and an absolute increase in the sum diameter of ≥5 millimeter (mm), the appearance of 1 or more new lesions and/or unequivocal progression of existing nontarget lesions.
Time frame: Baseline to Disease Progression or Death Due to Any Cause (Up To 32 Months)
Part C and D: Progression Free Survival (PFS)
For each participant in Part C and D who is not known to have died or to have had a progression of disease as of the data inclusion cut-off date, PFS was censored at the date of last objective progression-free disease assessment prior to the date of any subsequent systemic anticancer therapy. Progressive disease (PD) was determined using Response Evaluation Criteria In Solid Tumors (RECIST 1.1) criteria. PD is ≥20% increase in sum of longest diameter of target lesions and/or a new lesion.
Time frame: Baseline to Progressive Disease or Death from Any Cause (Up To 32 Months)
| Milestone | Part A: Cohort 1 | Part A: Cohort 2 | Part A: Cohort 3 | Part A: Cohort 4 | Part A: Cohort 5 | Part C | Part D |
|---|---|---|---|---|---|---|---|
| Started | 3 | 6 | 3 | 6 | 7 | 19 | 40 |
| Received at least one dose of drug | 3 | 6 | 3 | 6 | 7 | 19 | 40 |
| Completed | 3 | 6 | 3 | 6 | 7 | 19 | 40 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Recommended Phase 2 dose was determined by maximum tolerated dose (MTD), which was determined by Dose-limiting toxicity (DLT). For the purpose of this study, the MTD was defined as the highest tested dose that had \<33% probability of causing a DLT in Cycle 1 of Part A.
| milligrams (mg) | All Part A Participants |
|---|---|
| Recommended Phase 2 Dose: Maximum Tolerated Dose | 400 |
Pharmacokinetics (PK): 1.Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC\[0-∞\])
| nanogram*hour/milliliter (μg*h/mL) | 50 mg Taladegib | 100 mg Taladegib | 200 mg Taladegib | 400 mg Taladegib | 600 mg Taladegib |
|---|---|---|---|---|---|
| Cycle 1, Day 1 | NA ± NA | 8.70 ± 101 | NA ± NA | 53.7 ± 99.1 | 96.2 ± 74.8 |
| Cycle 1, Day 15 | NA ± NA | 12.4 ± 113 | NA ± NA | 93.8 ± 103 | NA ± NA |
PK: Maximum Observed Drug Concentration (Cmax)
| microgram per milliliter (μg/mL) | 50 mg Taladegib | 100 mg Taladegib | 200 mg Taladegib | 400 mg Taladegib | 600 mg Taladegib |
|---|---|---|---|---|---|
| Cycle 1, Day 1 | NA ± NA | 0.45 ± 59.87 | 1.29 ± NA | 2.07 ± 66.39 | 3.28 ± 34.36 |
| Cycle 1, Day 15 | NA ± NA | 0.71 ± 71.67 | NA ± NA | 3.62 ± 59.00 | NA ± NA |
PK: Time of Maximal Concentration (Tmax)
| hour (h) | 50 mg Taladegib | 100 mg Taladegib | 200 mg Taladegib | 400 mg Taladegib | 600 mg Taladegib |
|---|---|---|---|---|---|
| Cycle 1, Day 1 | 2.03 (2.00 to 2.22) | 3.92 (2.00 to 4.00) | 1.22 (0.75 to 4.00) | 2.00 (0.02 to 24.17) | 3.82 (1 to 6) |
| Cycle 1,Day 15 | 2.0 (1.00 to 4.05) | 4.10 (3.78 to 7.80) | 1.00 (0.92 to 1.88) | 2.00 (0.50 to 10.00) | 4.08 (0.88 to 8.00) |
PK: Area Under the Plasma Concentration-time Curve from time Zero to 24 Hours (AUC\[0-24\]) of LSN3185556
| microgram*hour/milliliter (μg*h/mL) | 50 mg Taladegib | 100 mg Taladegib | 200 mg Taladegib | 400 mg Taladegib | 600 mg Taladegib |
|---|---|---|---|---|---|
| Cycle 1, Day 1 | NA ± NA | 7.91 ± 50.1 | NA ± NA | 36.6 ± 70.1 | 67.4 ± 67.7 |
| Cycle 1, Day 15 | NA ± NA | 22.9 ± 67.6 | NA ± NA | 121 ± 81.0 | NA ± NA |
PK: Maximum Observed Drug Concentration (Cmax) of LSN3185556
| microgram per milliliter (μg/mL) | 50 mg Taladegib | 100 mg Taladegib | 200 mg Taladegib | 400 mg Taladegib | 600 mg Taladegib |
|---|---|---|---|---|---|
| Cycle 1, Day 1 | NA ± NA | 0.51 ± 37.28 | NA ± NA | 2.27 ± 62.82 | 4.18 ± 73.72 |
| Cycle 1, Day 15 | NA ± NA | 1.53 ± 60.18 | NA ± NA | 7.18 ± 72.20 | NA ± NA |
PK: Time of Maximal Concentration (Tmax)
| hour (h) | 50 mg Taladegib | 100 mg Taladegib | 200 mg Taladegib | 400 mg Taladegib | 600 mg Taladegib |
|---|---|---|---|---|---|
| Cycle 1, Day 1 | 24.25 (8.00 to 24.48) | 16.81 (6.12 to 24.43) | 6.00 (2.00 to 24.08) | 22.67 (1.13 to 25.17) | 24.00 (7.98 to 24.87) |
| Cycle 1,Day 15 | 8.00 (4.00 to 9.97) | 8.99 (3.78 to 10.00) | 8.00 (8.00 to 24.65) | 1.74 (0.00 to 24.92) | 8.00 (5.82 to 10.17) |
Clinical Benefit Rate is complete response (CR) + partial response (PR) + stable disease (SD) as classified by the investigator according to the Response Evaluation Criteria In Solid Tumors (RECIST version 1.1) guidelines. CR is disappearance of all target and non-target lesions; PR is ≥30% decrease in sum of longest diameter of target lesions. SD is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD). PD is a ≥20% increase in the sum of diameter of the target lesions taking as reference the smallest sum on study and an absolute increase in the sum diameter of ≥5 millimeter (mm), the appearance of 1 or more new lesions and/or unequivocal progression of existing nontarget lesions.
| Participants | Part A: Cohort 1 | Part A: Cohort 2 | Part A: Cohort 3 | Part A: Cohort 4 | Part A: Cohort 5 | Part C | Part D |
|---|---|---|---|---|---|---|---|
| Number of Participants With Clinical Benefit Rate (Stable Disease [SD] + Partial Response [PR] + Complete Response [CR]) | 2 | 1 | 2 | 1 | 2 | 4 | 37 |
For each participant in Part C and D who is not known to have died or to have had a progression of disease as of the data inclusion cut-off date, PFS was censored at the date of last objective progression-free disease assessment prior to the date of any subsequent systemic anticancer therapy. Progressive disease (PD) was determined using Response Evaluation Criteria In Solid Tumors (RECIST 1.1) criteria. PD is ≥20% increase in sum of longest diameter of target lesions and/or a new lesion.
| months | Part C | Part D |
|---|---|---|
| Part C and D: Progression Free Survival (PFS) | 1.74 (0.95 to 1.87) | 9.07 (7.36 to NA) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A: Cohort 1 | — | 0/3 (0%) | 3/3 (100%) |
| Part A: Cohort 2 | — | 3/6 (50%) | 6/6 (100%) |
| Part A: Cohort 3 | — | 0/3 (0%) | 3/3 (100%) |
| Part A: Cohort 4 | — | 3/6 (50%) | 6/6 (100%) |
| Part A: Cohort 5 | — | 1/7 (14.3%) | 7/7 (100%) |
| Part C | — | 4/19 (21.1%) | 19/19 (100%) |
| Part D | — | 10/40 (25%) | 40/40 (100%) |
| Event | Part A: Cohort 1 | Part A: Cohort 2 | Part A: Cohort 3 | Part A: Cohort 4 | Part A: Cohort 5 | Part C | Part D |
|---|---|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 0/3 | 0/6 | 0/3 | 2/6 | 1/7 | 0/19 | 1/40 |
| Abdominal painGastrointestinal disorders | 0/3 | 1/6 | 0/3 | 0/6 | 0/7 | 0/19 | 0/40 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 0/3 | 0/6 | 0/3 | 1/6 | 0/7 | 0/19 | 0/40 |
| VomitingGastrointestinal disorders | 0/3 | 0/6 | 0/3 | 1/6 | 1/7 | 0/19 | 0/40 |
| HyponatraemiaMetabolism and nutrition disorders | 0/3 | 1/6 | 0/3 | 0/6 | 0/7 | 0/19 | 0/40 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 0/3 | 1/6 | 0/3 | 0/6 | 0/7 | 1/19 | 0/40 |
| PneumoniaInfections and infestations | 0/3 | 0/6 | 0/3 | 0/6 | 0/7 | 2/19 | 0/40 |
| DeathGeneral disorders | 0/3 | 0/6 | 0/3 | 0/6 | 0/7 | 1/19 | 0/40 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/3 | 0/6 | 0/3 | 0/6 | 0/7 | 1/19 | 0/40 |
| AnaemiaBlood and lymphatic system disorders | 0/3 | 0/6 | 0/3 | 0/6 | 0/7 | 0/19 | 1/40 |
| Event | Part A: Cohort 1 | Part A: Cohort 2 | Part A: Cohort 3 | Part A: Cohort 4 | Part A: Cohort 5 | Part C | Part D |
|---|---|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 3/3 | 3/6 | 1/3 | 1/6 | 1/7 | 3/19 | 13/40 |
| FatigueGeneral disorders | 3/3 | 1/6 | 2/3 | 4/6 | 4/7 | 9/19 | 24/40 |
| VomitingGastrointestinal disorders | 1/3 | 2/6 | 1/3 | 5/6 | 3/7 | 7/19 | 16/40 |
| NauseaGastrointestinal disorders | 1/3 | 3/6 | 2/3 | 2/6 | 4/7 | 8/19 | 24/40 |
| Decreased appetiteMetabolism and nutrition disorders | 1/3 | 1/6 | 2/3 | 2/6 | 3/7 | 10/19 | 17/40 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 2/3 | 2/6 | 2/3 | 0/6 | 1/7 | 6/19 | 23/40 |
| DysgeusiaNervous system disorders | 2/3 | 3/6 | 2/3 | 1/6 | 4/7 | 8/19 | 23/40 |
| AlopeciaSkin and subcutaneous tissue disorders | 2/3 | 1/6 | 2/3 | 0/6 | 1/7 | 4/19 | 21/40 |
| RashSkin and subcutaneous tissue disorders | 2/3 | 0/6 | 0/3 | 0/6 | 0/7 | 2/19 | 2/40 |
| Weight decreasedInvestigations | 0/3 | 0/6 | 0/3 | 0/6 | 0/7 | 5/19 | 21/40 |
All participants who received at least one dose of study drug.
| Age, Continuous(years) | Part A: Cohort 1 | Part A: Cohort 2 | Part A: Cohort 3 | Part A: Cohort 4 | Part A: Cohort 5 | Part C | Part D | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 60.3 ± 14.57 | 57.2 ± 14.18 | 67.3 ± 7.37 | 60.7 ± 14.05 | 65.6 ± 11.34 | 62.5 ± 10.59 | 64.0 ± 12.47 | 63.1 ± 11.92 |
| Sex: Female, Male(Participants) | Part A: Cohort 1 | Part A: Cohort 2 | Part A: Cohort 3 | Part A: Cohort 4 | Part A: Cohort 5 | Part C | Part D | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 1 | 2 | 1 | 3 | 2 | 6 | 8 | 23 |
| Male | 2 | 4 | 2 | 3 | 5 | 13 | 32 | 61 |
| Ethnicity (NIH/OMB)(Participants) | Part A: Cohort 1 | Part A: Cohort 2 | Part A: Cohort 3 | Part A: Cohort 4 | Part A: Cohort 5 | Part C | Part D | Total |
|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 1 | 0 | 0 | 1 | 2 | 4 |
| Not Hispanic or Latino | 3 | 6 | 2 | 6 | 7 | 18 | 38 | 80 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Part A: Cohort 1 | Part A: Cohort 2 | Part A: Cohort 3 | Part A: Cohort 4 | Part A: Cohort 5 | Part C | Part D | Total |
|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 |
| White | 3 | 6 | 3 | 6 | 7 | 18 | 36 | 79 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Region of Enrollment(Participants) | Part A: Cohort 1 | Part A: Cohort 2 | Part A: Cohort 3 | Part A: Cohort 4 | Part A: Cohort 5 | Part C | Part D | Total |
|---|---|---|---|---|---|---|---|---|
| United States | 3 | 6 | 3 | 6 | 7 | 19 | 40 | 84 |
Plan to share: No
No publications or documents are linked to this record.
The record gives a start of Sep 2010, a primary completion of Jan 2015 and a completion of Oct 2017. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2019, 4 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: LY2940680